Optimizing care for high-risk neuroblastoma patients treated with dinutuximab: Challenges for the multidisciplinary team.
Tiene BautersVeronique Van de VeldeStefanie BekaertGeneviève LaureysPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Current treatment protocols for high-risk neuroblastoma include high-dose chemotherapy, surgery, stem cell transplantation and radiation. Recently, dinutuximab, a chimeric monoclonal antibody, specifically targeting the disialoganglioside highly expressed on neuroblastoma cells, has been licensed. Its incorporation in maintenance therapy represents a promising treatment approach. The introduction of its use was a challenge for the entire multidisciplinary team in our pediatric hematology and oncology ward just as for the pharmacy team. An overview of the key points that were observed is presented.
Keyphrases
- high dose
- stem cell transplantation
- palliative care
- quality improvement
- monoclonal antibody
- healthcare
- low dose
- induced apoptosis
- stem cells
- cell therapy
- coronary artery bypass
- combination therapy
- coronary artery disease
- mesenchymal stem cells
- young adults
- drug delivery
- atrial fibrillation
- pain management
- cell cycle arrest
- cancer therapy
- radiation induced
- acute coronary syndrome
- percutaneous coronary intervention